Zurich - BC Platforms intends to consolidate its position as the leading European supplier of real-world health data following an investment of 20 million Swiss francs. Life Sciences firms can use this data from Europe and Asia to drive the development of effective medicines.

BC Platforms (BCP) has announced that it has successfully closed a financing round. This was led by the Paris-based private equity firm Jolt Capital, which specializes in providing growth capital for European DeepTech firms. As a result, BCP has increased its equity capital by 20 million Swiss francs.

As the press release explains further, this fresh capital injection will help to accelerate the expansion of the company’s data footprint in addition to consolidating its position as the leading European data provider and enabler of personalized precision medicine. The focus here is on the procurement of clinically valuable real-world data from European and Asian countries.

“The goal is to provide users of BCP’s services, which include over ten of the world’s largest pharmaceutical companies, with over 100 million accessible subjects by 2026”, the press release states. The company is already represented in the USA, the UK, Finland, Switzerland and Singapore. This data should serve to accelerate research innovation across the industry. “BCP is on track to emerge as a global leader”, explains Laurent Samama, Managing Partner at Jolt Capital.

This “significant investment” is providing a “powerful boost” to BCP’s mission, according to Tero Silvola, CEO of BCP, who adds: “We will also be looking to build synergistic capabilities through future acquisitions”.

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?  
info@greaterzuricharea.com